KMDA ▲ +0.2% - Kamada Ltd. $KMDA - CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand Kamada rose 0.2% after the CDC reported a significant increase in U.S. rabies exposures and anti-rabies immunoglobulin utilization, prompting the company to confirm it has sufficient supply of its KedRAB® product to meet the heightened demand. The announcement positions Kamada to potentially benefit from increased usage of its rabies treatment as exposures climb. 17-SEP-2026 07:00 AM ET